Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.73 |
| ▸ | PPARA | Q07869 | 18/20 | 0.73 |
| ▸ | PTGES | O14684 | 1/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8935946 | 1.00 | PPARG (0.73) | PPARGPPARAPTGESALOX5 | |
| SCHEMBL289442 | 0.89 | PPARG (0.64) | PPARGPPARAPTGESALOX5 | |
| SCHEMBL8935884 | 0.89 | PPARG (0.64) | PPARGPPARAPTGESALOX5 | |
| SCHEMBL557511 | 0.88 | CTRC (0.62) | PPARGPPARAPTGESALOX5 | |
| SCHEMBL22828775 | 0.86 | CTRC (0.64) | PPARGPPARAPTGESALOX5 | |
| SCHEMBL15903011 | 0.86 | CTRC (0.64) | PPARGPPARAPTGESALOX5 | |
| SCHEMBL6342298 | 0.86 | CTRC (0.64) | PPARGPPARAPTGESALOX5 | |
| SCHEMBL4002165 | 0.86 | CTRC (0.64) | PPARGPPARAPTGESALOX5 | |
| SCHEMBL11531304 | 0.86 | CTRC (0.64) | PPARGPPARAPTGESALOX5 | |
| SCHEMBL4001414 | 0.86 | CTRC (0.64) | PPARGPPARAPTGESALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | claimed |
| EP-4663187-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | Laminar Pharmaceuticals, S.A. (ES) | 2025-12-17 | — | — | EP | claimed |
| WO-2024189252-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S.A. (ES) | 2024-09-19 | — | — | WO | claimed |
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | WASHINGTON UNIVERSITY | 2022-11-24 | — | — | US | claimed |
| EP-4031124-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | Reneo Pharmaceuticals, Inc. (US) | 2022-07-27 | — | — | EP | claimed |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | RENEO PHARMACEUTICALS, INC. | 2022-04-21 | — | — | US | claimed |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | RENEO PHARMACEUTICALS, INC. | 2022-01-27 | — | — | US | claimed |
| EP-3927718-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | Reneo Pharmaceuticals, Inc. (US) | 2021-12-29 | — | — | EP | claimed |
| EP-3920903-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | Reneo Pharmaceuticals, Inc. (US) | 2021-12-15 | — | — | EP | claimed |
| WO-2021055725-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | RENEO PHARMACEUTICALS, INC. (US) | 2021-03-25 | — | — | WO | claimed |
| WO-2020163240-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | RENEO PHARMACEUTICALS, INC. (US) | 2020-08-13 | — | — | WO | claimed |
| EP-2610245-A1 | Pipecolate-sulfonamides for treatment of psychiatric disorders | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2013-07-03 | — | — | EP | claimed |
| US-20050267168-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2005-12-01 | — | — | US | claimed |
| US-20030096802-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. | 2003-05-22 | — | — | US | claimed |
| US-6201021-B1 | TREATMENT OF DISEASES INDUCED BY REACTIVE ASTROCYTES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-03-13 | — | — | US | claimed |
| EP-0632008-B1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO (JP) | 1998-02-04 | — | — | EP | claimed |
| EP-0632008-A1 | Pentanoic acid derivatives | ONO PHARMACEUTICAL CO., LTD. (JP) | 1995-01-04 | — | — | EP | claimed |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | LAMINAR PHARMACEUTICALS S A (ES) | 2026-04-30 | — | — | US | disclosed |
| US-3954981-A | Triazolocycloalkylhydrothiadiazine derivatives | RICHARDSON-MERRELL INC. (US) | 1976-05-04 | — | — | US | disclosed |
| US-3933885-A | Cinnamylideneacetic acid esters | FUJI PHOTO FILM CO., LTD. (JA) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267168-A1 | Pentanoic acid derivatives | FFAR3, FFAR1, HCAR3 | PPARG 510/4885PPARA 540/4885PTGES 2520/4885 |
| US-20030096802-A1 | Pentanoic acid derivatives | FFAR3, FPR1, FPR3 | PPARG 932/4885PPARA 796/4885PTGES 1968/4885 |
| US-20220370467-A1 | USING OF A PPAR-DELTA AGONIST IN THE TREATMENT OF KIDNEY DISEASE | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885PTGES 224/4885 |
| US-20220117972-A1 | USE OF PPAR-DELTA AGONISTS IN THE TREATMENT OF MITOCHONDRIAL MYOPATHY | PPARD, PPARA, MTPN | PPARG 4/4885PPARA 2/4885PTGES 929/4885 |
| US-20220023306-A1 | USE OF A PPAR-DELTA AGONIST IN THE TREATMENT OF FATTY ACID OXIDATION DISORDERS (FAOD) | PPARD, ACOX1, CPT1A | PPARG 4/4885PPARA 8/4885PTGES 578/4885 |
| US-20260115161-A1 | 2-HYDROXY-OCTADECENE-9-CIS-OATE FOR USE IN THE TREATMENT OF ONCOLOGICAL PATHOLOGIES AND NEUROPATHIC PAIN | PMP22, VHL, PAX8 | PPARG 1024/4885PPARA 1762/4885PTGES 528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.